A Phase 2 Study of Futibatinib in Combination with PD-1 Antibody-based Standard of Care Therapy in Patients with Solid Tumors

Disease Types: Gastrointestinal, Pancreatic, Solid Tumors

Available at: AlleghanyBlacksburgRoanokeSalemWytheville

A Phase 2 Study of Futibatinib in Combination with PD-1 Antibody-based Standard of Care Therapy in Patients with Solid Tumors 

For More Information:

https://clinicaltrials.gov/study/NCT05945823?term=A%20Phase%202%20Study%20of%20Futibatinib%20in%20Combination%20with%20PD-1%20Antibody-based%20Standard%20of%20Care%20Therapy%20in%20Patients%20with%20Solid%20Tumors%20&rank=1

Parallel Phase III randomized trials for high risk prostate cancer evaluating de-intensification for lower genomic risk and intensification of concurrent therapy for higher genomic risk with radiation

Disease Types: Prostate

Available at: Roanoke

Parallel Phase III randomized trials for high risk prostate cancer evaluating de-intensification for lower genomic risk and intensification of concurrent therapy for higher genomic risk with radiation

For More Information:

https://clinicaltrials.gov/study/NCT04513717?term=Parallel%20Phase%20III%20randomized%20trials%20for%20high%20risk%20prostate%20cancer%20evaluating%20de-intensification%20for%20lower%20genomic%20risk%20and%20intensification%20of%20concurrent%20therapy%20for%20higher%20genomic%20risk%20with%20radiation&rank=1

A Phase Ib/II, open-label, multicenter study evaluating the safety, activity, and pharmacokinetics of GDC-6036 in combination with other anti-cancer therapies in patients with previously untreated advanced or metastatic non-small cell lung cancer with a KRAS G12C mutation

Disease Types: Lung

Available at: AlleghanyBlacksburgRoanokeSalemWytheville

A Phase Ib/II, open-label, multicenter study evaluating the safety, activity, and pharmacokinetics of GDC-6036 in combination with other anti-cancer therapies in patients with previously untreated advanced or metastatic non-small cell lung cancer with a KRAS G12C mutation

For More Information:

https://clinicaltrials.gov/study/NCT04449874?term=NSCLC%20G12C%20mutation%20GDC-6036%20&rank=1

A Phase 2 Study of Alisertib in Patients with Extensive Small Cell Lung Cancer

Disease Types: Lung

Available at: AlleghanyBlacksburgRoanokeSalemWytheville

A Phase 2 Study of Alisertib in Patients with Extensive Small Cell Lung Cancer

For More information:

https://clinicaltrials.gov/study/NCT06095505?term=A%20Phase%202%20Study%20of%20Alisertib%20in%20Patients%20with%20Extensive%20Small%20Cell%20Lung%20Cancer&rank=1

A randomized, phase 3, open-label study to evaluate SGN-B6A compared with docetaxel in adult subjects with previously treated non-small cell lung cancer

Disease Types: Lung

Available at: AlleghanyBlacksburgRoanokeSalemWytheville

A randomized, phase 3, open-label study to evaluate SGN-B6A compared with docetaxel in adult subjects with previously treated non-small cell lung cancer 

For More Information:

https://clinicaltrials.gov/study/NCT06012435?term=A%20randomized,%20phase%203,%20open-label%20study%20to%20evaluate%20SGN-B6A%20compared%20with%20docetaxel%20in%20adult%20subjects%20with%20previously%20treated%20non-small%20cell%20lung%20cancer%20&rank=1

A Phase 3, Randomized, Multi-center, Open-label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-low, Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy

Disease Types: Breast

Available at: AlleghanyBlacksburgRoanokeSalemWytheville

A Phase 3, Randomized, Multi-center, Open-label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-low, Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy

For More Information:

https://clinicaltrials.gov/study/NCT06018337?term=A%20Phase%203,%20Randomized,%20Multi-center,%20Open-label%20Study%20of%20DB-1303%20Versus%20Investigator%27s%20Choice%20Chemotherapy%20in%20Human%20Epidermal%20Growth%20Factor%20Receptor%202%20(HER2)-low,%20Hormone%20Receptor%20Positive%20(HR%2B)%20Metastatic%20Breast%20Cancer%20Patients%20whose%20Disease%20has%20Progressed%20on%20Endocrine%20Therapy&rank=1

A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physicians Choice in Patients with Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy

Disease Types: Breast

Available at: AlleghanyBlacksburgRoanokeSalemWytheville

 A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physicians Choice in Patients with Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy

For More Information:

https://clinicaltrials.gov/study/NCT05633654?term=%20A%20Randomized,%20Open-label,%20Phase%203%20Study%20of%20Adjuvant%20Sacituzumab%20Govitecan%20and%20Pembrolizumab%20Versus%20Treatment%20of%20Physicians%20Choice%20in%20Patients%20with%20Triple%20Negative%20Breast%20Cancer%20Who%20Have%20Residual%20Invasive%20Disease%20After%20Surgery%20and%20Neoadjuvant%20Therapy&rank=1

A Phase 3, Randomized, Open-label Study of MK-5684 versus Alternative Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) and Have Progressed On or After Prior Treatment with One Next-generation Hormonal Agent (NHA) for Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

Disease Types: Prostate

Available at: AlleghanyBlacksburgRoanokeWythevilleSalem

A Phase 3, Randomized, Open-label Study of MK-5684 versus Alternative Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) and Have Progressed On or After Prior Treatment with One Next-generation Hormonal Agent (NHA) for Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

For More Information:

https://clinicaltrials.gov/study/NCT06136650?term=MK-5684&rank=4

A Phase 3 Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) Previously Treated With Next-generation Hormonal Agent (NHA) and Taxane-based Chemotherapy

Disease Types: Prostate

Available at: AlleghanyBlacksburgRoanokeSalemWytheville

A Phase 3 Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) Previously Treated With Next-generation Hormonal Agent (NHA) and Taxane-based Chemotherapy

For More Information:

https://clinicaltrials.gov/study/NCT06136624?term=A%20Phase%203%20Randomized,%20Open-label%20Study%20of%20MK-5684%20Versus%20Alternative%20Abiraterone%20Acetate%20or%20Enzalutamide%20in%20Participants%20With%20Metastatic%20Castration-resistant%20Prostate%20Cancer%20(mCRPC)%20Previously%20Treated%20With%20Next-generation%20Hormonal%20Agent%20(NHA)%20and%20Taxane-based%20Chemotherapy&rank=1

Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma (Previously Grade 1-3a): Epcoritamab in Outpatient Setting

Disease Types: Lymphoma

Available at: Roanoke

Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma (Previously Grade 1-3a): Epcoritamab in Outpatient Setting

For More Information:

https://clinicaltrials.gov/study/NCT05451810?term=Relapsed%20or%20Refractory%20Diffuse%20Large%20B-Cell%20Lymphoma%20and%20Classic%20Follicular%20Lymphoma%20(Previously%20Grade%201-3a):%20Epcoritamab%20in%20Outpatient%20Setting&rank=1

A Randomized, Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination with Investigational Agents as First-Line Treatment in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (BGB-HNSCC-201)

Disease Types: Head and Neck

Available at: AlleghanyBlacksburgRoanokeSalemWytheville

A Randomized, Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination with Investigational Agents as First-Line Treatment in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (BGB-HNSCC-201)

For More Information:

https://clinicaltrials.gov/study/NCT05909904?term=%09NCT05909904&rank=1

A multicenter, open-label, phase 2, basket study to evaluate the efficacy and safety of SKB264 in combination with pembrolizumab in subjects with selected solid tumors (SKB264-II-06)

Disease Types: Bladder, Ovarian, Solid Tumors

Available at: AlleghanyBlacksburgRoanokeSalemWytheville

A multicenter, open-label, phase 2, basket study to evaluate the efficacy and safety of SKB264 in combination with pembrolizumab in subjects with selected solid tumors (SKB264-II-06)

For More Information:

https://clinicaltrials.gov/study/NCT05642780?term=NCT05642780&rank=1

A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide with Continued Versus Intermittent Androgen-Deprivation Therapy (ADT) following PSA Response in Participants with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) (56021927PCR3020)

Disease Types: Prostate

Available at: AlleghanyBlacksburgRoanokeSalemWytheville

A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide with Continued Versus Intermittent Androgen-Deprivation Therapy (ADT) following PSA Response in Participants with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) (56021927PCR3020)

For More Information:

https://clinicaltrials.gov/study/NCT05884398?term=%09NCT05884398&rank=1

A Global, Phase 3, Randomized, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Furmonertinib Compared to Platinum-Based Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Insertion Mutations

Disease Types: Lung

Available at: AlleghanyBlacksburgRoanokeSalemWytheville

A Global, Phase 3, Randomized, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Furmonertinib Compared to Platinum-Based Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Insertion Mutations

For More Information:

https://clinicaltrials.gov/study/NCT05607550?term=NCT05607550&rank=1

A Phase 1/2 Study of Avutometinib (VS-6766) in Combination with Sotorasib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Disease Types: Lung

Available at: AlleghanyBlacksburgRoanokeSalemWytheville

A Phase 1/2 Study of Avutometinib (VS-6766) in Combination with Sotorasib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

For More Information:

https://clinicaltrials.gov/study/NCT05074810?term=NCT05074810&rank=1

A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001)

Disease Types: Breast

Available at: AlleghanyBlacksburgRoanokeSalemWytheville

A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001)

For More Information:

https://clinicaltrials.gov/study/NCT05774951?term=NCT05774951&rank=1

A multi-center, multi-country prospective observational study of patients initiating T-DXd in the first or second treatment line for HER2+, and HER2-low unresectable and/or metastatic breast cancer (DESTINY BREAST- RESPOND) (D9673R00025)

Disease Types: Breast

Available at: AlleghanyBlacksburgRoanokeSalemWytheville

A multi-center, multi-country prospective observational study of patients initiating T-DXd in the first or second treatment line for HER2+, and HER2-low unresectable and/or metastatic breast cancer (DESTINY BREAST- RESPOND) (D9673R00025)

For More Information:

https://clinicaltrials.gov/study/NCT05592483?term=%09NCT05592483&rank=1

An Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Multiple Solid Tumors

Disease Types: Gastrointestinal

Available at: AlleghanyBlacksburgRoanokeSalemWytheville

An Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Multiple Solid Tumors

For More Information:

https://clinicaltrials.gov/study/NCT04976634?term=An%20Open-label,%20Multicenter,%20Phase%202%20Study%20to%20Evaluate%20the%20Efficacy%20and%20Safety%20of%20Pembrolizumab%20Plus%20Lenvatinib%20in%20Combination%20With%20Belzutifan%20in%20Multiple%20Solid%20Tumors&rank=1

A Phase IIa/IIb, open-label, single-arm, multi-centre trial of BI 907828 for treatment of patients with locally advanced/ metastatic, MDM2 amplified, TP53 wild-type biliary tract adenocarcinoma, pancreatic ductal adenocarcinoma, or other selected solid tumours.

Disease Types: Pancreatic, Solid Tumors

Available at: AlleghanyBlacksburgRoanokeSalemWytheville

A Phase IIa/IIb, open-label, single-arm, multi-centre trial of BI 907828 for treatment of patients with locally advanced/ metastatic, MDM2 amplified, TP53 wild-type biliary tract adenocarcinoma, pancreatic ductal adenocarcinoma, or other selected solid tumours.

For More Information:

https://clinicaltrials.gov/study/NCT05512377?term=A%20Phase%20IIa%2FIIb,%20open-label,%20single-arm,%20multi-centre%20trial%20of%20BI%20907828%20for%20treatment%20of%20patients%20with%20locally%20advanced%2F%20metastatic,%20MDM2%20amplified,%20TP53%20wild-type%20biliary%20tract%20adenocarcinoma,%20pancreatic%20ductal%20adenocarcinoma,%20or%20other%20selected%20solid%20tumour&rank=1&limit=10

A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy

Disease Types: Colon

Available at: AlleghanyBlacksburgRoanokeSalemWytheville

A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy

For More Information:

https://clinicaltrials.gov/study/NCT04793958?term=A%20Randomized%20Phase%203%20Study%20of%20MRTX849%20in%20Combination%20with%20Cetuximab%20Versus%20Chemotherapy%20in%20Patients%20with%20Advanced%20Colorectal%20Cancer%20with%20KRAS%20G12C%20Mutation%20with%20Disease%20Progression%20On%20or%20After%20Standard%20First-Line%20Therapy&rank=1

A Phase 3 Study to Evaluate Zimberelimab (AB122) Combined with Domvanalimab (AB154) Compared to Pembrolizumab in Front-Line, PD-L1-High, Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Disease Types: Lung

Available at: AlleghanyBlacksburgRoanokeSalemWytheville

A Phase 3 Study to Evaluate Zimberelimab (AB122) Combined with Domvanalimab (AB154) Compared to Pembrolizumab in Front-Line, PD-L1-High, Locally Advanced or Metastatic Non-Small Cell Lung Cancer

For More Information:

https://clinicaltrials.gov/study/NCT04736173?term=A%20Phase%203%20Study%20to%20Evaluate%20Zimberelimab%20(AB122)%20Combined%20with%20Domvanalimab%20(AB154)%20Compared%20to%20Pembrolizumab%20in%20Front-Line,%20PD-L1-High,%20Locally%20Advanced%20or%20Metastatic%20Non-Small%20Cell%20Lung%20Cancer&rank=1

A Phase 3 Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy (TROPION-Breast03)(D926XC00001)

Disease Types: Breast

Available at: AlleghanyBlacksburgRoanokeSalemWytheville

A Phase 3 Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy (TROPION-Breast03)(D926XC00001)

For More Information:

https://clinicaltrials.gov/study/NCT05629585?term=A%20Phase%203%20Open-label,%20Randomised%20Study%20of%20Datopotamab%20Deruxtecan%20(Dato-DXd)%20With%20or%20Without%20Durvalumab%20Versus%20Investigator%27s%20Choice%20of%20Therapy%20in%20Patients%20With%20Stage%20I-III%20Triple-negative%20Breast%20Cancer%20Who%20Have%20Residual%20Invasive%20Disease%20in%20the%20Breast%20and%2For%20Axillary%20Lymph%20Nodes%20at%20Surgical%20Resection%20Following%20Neoadjuvant%20Systemic%20Therapy%20(TROPION-Breast03)(D926XC00001)&rank=1

Clinical Utility of Fluoroestradiol F18 PET/CT in Metastatic Breast Cancer Patients with ER-Positive and HER2-Negative Primary Lesions after Progression on First Line Hormonal Therapy

Disease Types: Breast

Available at: Roanoke

Fluoroestradiol F18 PET/CT in Metastatic Breast Cancer Patients with ER-Positive and HER2-Negative Primary Lesions

For More Information:

https://clinicaltrials.gov/study/NCT05068726?term=Fluoroestradiol%20F18%20PET%2FCT%20in%20Metastatic%20Breast%20Cancer%20Patients%20with%20ER-Positive%20and%20HER2-Negative%20Primary%20Lesions&rank=1

Randomized Phase II/III Trial Of Consolidation Radiation + Immunotherapy for ES-SCLC

Disease Types: Lung

Available at: Roanoke

Randomized Phase II/III Trial Of Consolidation Radiation + Immunotherapy for ES-SCLC

For More Information:

https://clinicaltrials.gov/ct2/show/NCT04402788?term=Randomized+Phase+II%2FIII+Trial+Of+Consolidation+Radiation+%2B+Immunotherapy+for+ES-SCLC&draw=2&rank=1

A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer with an Increased Risk of Recurrence

Disease Types: Breast

Available at: AlleghanyBlacksburgRoanokeSalemWytheville

A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer with an Increased Risk of Recurrence

For More information:

https://clinicaltrials.gov/ct2/show/NCT05514054?term=Adjuvant+Imlunestrant+vs+Standard+Adjuvant+Endocrine+Therapy+in+breast+cancer&draw=2&rank=1

A Phase 3, Open-Label, Randomized, Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive, HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy

Disease Types: Breast

Available at: AlleghanyBlacksburgRoanokeWythevilleSalem

A Phase 3, Open-Label, Randomized, Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive, HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy 

For More Information:

https://clinicaltrials.gov/ct2/show/NCT05501886?term=Gedatolisib+in+Combination+with+Palbociclib+and+Fulvestrant&draw=2&rank=4

A Phase I-III, Multicenter Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Patients Selected According to Biomarker Status, with locally advanced, unresectable, Stage III Non-Small Cell Lung Cancer

Disease Types: Lung

Available at: AlleghanyBlacksburgRoanokeSalemWytheville

A Phase I-III, Multicenter Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Patients Selected According to Biomarker Status, with locally advanced, unresectable, Stage III Non-Small Cell Lung Cancer

For More Information:

https://clinicaltrials.gov/ct2/show/NCT05170204?term=A+Phase+I-III%2C+Multicenter+Study+Evaluating+the+Efficacy+and+Safety+of+Multiple+Therapies+in+Cohorts+of+Patients+Selected+According+to+Biomarker+Status%2C+with+locally+advanced%2C+unresectable%2C+Stage+III+Non-Small+Cell+Lung+Cancer&draw=2&rank=1

A Phase 2 multi-center open-label basket trial of nab-sirolimus for adult and adolescent patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (TSC-007)

Disease Types: Solid Tumors

Available at: AlleghanyBlacksburgRoanokeSalemWytheville

A Phase 2 multi-center open-label basket trial of nab-sirolimus for adult and adolescent patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (TSC-007)

For More Information:

https://clinicaltrials.gov/ct2/show/NCT05103358?term=A+Phase+2+multi-center+open-label+basket+trial+of+nab-sirolimus+for+adult+and+adolescent+patients+with+malignant+solid+tumors+harboring+pathogenic+inactivating+alterations+in+TSC1+or+TSC2+genes+%28TSC-007%29&draw=2&rank=1

A Phase 1B/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker adaptive study of Tazemetostat or placebo in combination with lenalidomide plus rituximab in subjects with relapsed/refractory Follicular Lymphoma (EZH-302)

Disease Types: Lymphoma

Available at: AlleghanyBlacksburgRoanokeSalemWytheville

A Phase 1B/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker adaptive study of Tazemetostat or placebo in combination with lenalidomide plus rituximab in subjects with relapsed/refractory Follicular Lymphoma (EZH-302)

For More Information:

https://clinicaltrials.gov/ct2/show/NCT04224493?term=A+Phase+1B%2F3+Double-Blind%2C+Randomized%2C+Active-Controlled%2C+3-Stage%2C+Biomarker+adaptive+study+of+Tazemetostat+or+placebo+in+combination+with+lenalidomide+plus+rituximab+in+subjects+with+relapsed%2Frefractory+Follicular+Lymphoma+%28EZH-302%29&draw=2&rank=1

Master Screening Study to determine biomarker status and potential trial eligibility for patients with malignant tumors

Disease Types: Lung

Available at: AlleghanyBlacksburgRoanokeSalemWytheville

Master Screening Study to determine biomarker status and potential trial eligibility for patients with malignant tumors

For More Information:

https://clinicaltrials.gov/ct2/show/NCT05419375?term=Master+Screening+Study+to+determine+biomarker+status+and+potential+trial+eligibility+for+patients+with+malignant+tumors&draw=2&rank=1

Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer

Disease Types: Colon

Available at: AlleghanyBlacksburgRoanokeSalemWytheville

Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer

For more information:

https://clinicaltrials.gov/ct2/show/NCT05425940?term=Study+of+XL092+%2B+Atezolizumab+vs+Regorafenib+in+Subjects+With+Metastatic+Colorectal+Cancer&draw=2&rank=1

A phase 2 study of brentuximab vedotin in combination with pembrolizumab in subjects with metastatic solid malignancies after progression on prior PD-1 inhibitor treatment

Disease Types: Lung, Melanoma

Available at: AlleghanyBlacksburgRoanokeSalemWytheville

A phase 2 study of brentuximab vedotin in combination with pembrolizumab in subjects with metastatic solid malignancies after progression on prior PD-1 inhibitor treatment 

For more information:

https://clinicaltrials.gov/ct2/show/NCT04609566?cond=A+phase+2+study+of+brentuximab+vedotin+in+combination+with+pembrolizumab+in+subjects+with+metastatic+solid+malignancies+after+progression+on+prior+PD-1+inhibitor+treatment&draw=2&rank=1

A Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer After Failure of Platinum-Based Regimen or Anti-PD-1/PD-L1 Based Immunotherapy (IMMU-132-06)

Disease Types: Bladder

Available at: AlleghanyBlacksburgRoanokeSalemWytheville

A Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer After Failure of Platinum-Based Regimen or Anti-PD-1/PD-L1 Based Immunotherapy (IMMU-132-06)

For more information:

https://clinicaltrials.gov/ct2/show/NCT03547973?term=IMMU-132-06&draw=2&rank=1